Chemohormonal Therapy for Hormone-Sensitive Newly Metastatic Prostate Cancer

Speaker: Joaquim Bellmunt

Ten years after pivotal results of docetaxel in castration-resistant prostate cancer, J.Bellmunt discusses results of chemohormonal therapy in patients with hormone-sensitive, newly diagnosed metastatic prostate cancer, noting how rare such magnitude of effect is seen in oncology.

Discussion Points

  • What did this study test and what are the study (topline) results?
  • How would you interpret these findings with respect to the current standard of care for hormone-sensitive newly metastatic prostate cancer?